Do different formulations of botulinum toxin type A really have different migration characteristics?

نویسندگان

  • Syrus Karsai
  • Christian Raulin
چکیده

Do different formulations of botulinum toxin type A really have different migration characteristics? The dose units of the two main botulinum toxin A products are not equivalent, and there is continuing controversy about the appropriate dose conversion ratio. Cliff et al . 1 report on a study of anhidrotic halos after injections of Dysport and Botox to the forehead at a dose ratio of 3 : 1. They note that the areas of the halos are significantly greater after Dysport and conclude that this product diffuses more. Similar results and conclusions have been published by de Almeida and De Boulle. 2 Both studies were sponsored by Allergan. We performed a non-commercially sponsored study on the effects of Dysport and Botox at a dose ratio of 3 : 1 on forehead wrinkles and electromyographic activity, and found Dysport to have significantly more effect on both. 3 We therefore agree with the results of Cliff et al . but not their conclusion. The simplest explanation for both sets of results is that the dose of Dysport is higher (i.e., a ratio 3 : 1 is too high). In this context, it should be noted that the registered doses of Dysport and Botox/Vistabel for glabellar frown lines are 50 and 20 units, respectively (i.e., a unit ratio of 2.5 : 1). Although higher ratios are often quoted in the literature, more modern investigations in human models suggest that the correct conversion ratio is around 2.5 : 1 or lower and physicians using both products should be aware of this issue and not overdose with Dysport. Syrus Karsai, MD 1 & Christian Raulin, MD 1,2 1 Laserklinik Karlsruhe, Karlsruhe, Germany, 2 Department of Dermatology, University of Heidelberg, Heidelberg, Germany

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Double Sandwich ELISA Modified Method for the Detection of Clostridium Botulinum Type E

Background & Objective: A very small amount of botulinum toxin can cause death and on the other hand, there is no cure for its poison other than antitoxin. Therefore, a diagnostic method that can detect very small amounts of botulinum toxin in a short time is very important. In this study, rapid and accurate detection of botulinum toxin type E has been performed with the double sandwich ELISA m...

متن کامل

Using translational medicine to understand clinical differences between botulinum toxin formulations.

When using botulinum toxin-based products, the physician must decide the optimal location and dose required to alleviate symptoms and improve the patient's quality of life. To deliver effective treatment, the physician needs to understand the importance of accurate target muscle selection and localization and the implications of each product's migration properties when diluted in different volu...

متن کامل

Aesthetic Applications of Botulinum Toxin A in Asians: An International, Multidisciplinary, Pan-Asian Consensus

BACKGROUND Botulinum toxin type A remains the most popular nonsurgical aesthetic treatment worldwide. Previous consensus statements have focused on Caucasians and on Koreans as generally representative of Asians. However, indications and dosages vary among different ethnic groups. This publication reports the results of a multidisciplinary, pan-Asian consensus focusing on incobotulinumtoxinA. ...

متن کامل

Anti-cancer Potential of Captopril and Botulinum Toxin Type-A and Associated p53 Gene Apototic Stimulating Activity

Mutational inactivation of p53 is a key player in the development of human cancer. Thus, retrieving the tumor suppressor activity of p53 gene is considered a novel strategy in cancer therapy. Current study aimed to investigate the anti-cancer potentials of botulinum toxin type-A (BTX-A) and captopril as a trial to shed light on effective anti-cancer therapy with lower side effects. Cytotoxic ef...

متن کامل

Anti-cancer Potential of Captopril and Botulinum Toxin Type-A and Associated p53 Gene Apototic Stimulating Activity

Mutational inactivation of p53 is a key player in the development of human cancer. Thus, retrieving the tumor suppressor activity of p53 gene is considered a novel strategy in cancer therapy. Current study aimed to investigate the anti-cancer potentials of botulinum toxin type-A (BTX-A) and captopril as a trial to shed light on effective anti-cancer therapy with lower side effects. Cytotoxic ef...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of cosmetic dermatology

دوره 7 3  شماره 

صفحات  -

تاریخ انتشار 2008